Wall Street analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report $525.03 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for IDEXX Laboratories’ earnings, with the lowest sales estimate coming in at $522.70 million and the highest estimate coming in at $527.53 million. IDEXX Laboratories posted sales of $462.02 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.6%. The company is scheduled to announce its next quarterly earnings report on Friday, April 27th.
According to Zacks, analysts expect that IDEXX Laboratories will report full-year sales of $525.03 million for the current year, with estimates ranging from $2.21 billion to $2.23 billion. For the next financial year, analysts anticipate that the company will post sales of $2.45 billion per share, with estimates ranging from $2.43 billion to $2.46 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million for the quarter, compared to analysts’ expectations of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The company’s revenue was up 14.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.58 EPS.
IDEXX Laboratories (IDXX) opened at $180.05 on Wednesday. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. IDEXX Laboratories has a one year low of $140.63 and a one year high of $198.73. The firm has a market cap of $15,730.77, a price-to-earnings ratio of 57.08, a PEG ratio of 2.22 and a beta of 0.58.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $153.61, for a total value of $2,764,980.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at approximately $163,529,058.53. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan W. Ayers sold 2,160 shares of IDEXX Laboratories stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the sale, the chief executive officer now owns 1,077,112 shares in the company, valued at $179,910,017.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 58,160 shares of company stock worth $9,080,905. 2.77% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Advisors Capital Management LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $262,000. Koch Industries Inc. increased its holdings in IDEXX Laboratories by 44,533.1% in the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares during the last quarter. Wells Fargo & Company MN increased its holdings in IDEXX Laboratories by 7.8% in the 3rd quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock valued at $52,706,000 after acquiring an additional 24,510 shares during the last quarter. Cabot Wealth Management Inc. bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $1,359,000. Finally, Macquarie Group Ltd. increased its holdings in IDEXX Laboratories by 7.0% in the 3rd quarter. Macquarie Group Ltd. now owns 38,000 shares of the company’s stock valued at $5,909,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors own 86.72% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “$525.03 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/07/525-03-million-in-sales-expected-for-idexx-laboratories-inc-idxx-this-quarter.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.